Chemotherapy targeting by DNA capture in viral protein particles

Nanomedicine

Volumn 7, Issue 3, 2012, Pages 335-352

  Agadjanian, Hasmik ^a   Chu, David ^a   Hwang, Jae Youn ^a   Wachsmann Hogiu, Sebastian ^a   Rentsendorj, Altan ^a   Song, Lei ^a   Valluripalli, Vinod ^a   Lubow, Jay ^a   Ma, Jun ^a   Sharifi, Behrooz ^a   Farkas, Daniel L ^a   Medina Kauwe, Lali K ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

doxorubicin; HER; herdox; nanoparticle; noncovalent; penton base; self assembly; tumor targeting; viral capsid

Indexed keywords

DNA; DOXORUBICIN; ELECTROPHILE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOPARTICLE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CYTOTOXICITY; DNA CAPTURE; DNA DRUG COMPLEX; DNA INTERCALATION; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HEART; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DNA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HUMANS; MICE; NANOPARTICLES; NEOPLASMS; RECEPTOR, ERBB-2; SERUM; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857802702     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.104     Document Type: Article

References (59)

1. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: A comprehensive review. Prog. Cardiovasc. Dis. 53(2), 94-104 (2010).
2. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2, 188-200 (2002).
3. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 100(1), 135-144 (2004).
4. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Control. Release 100(2), 247-256. (2004).
5. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29(6), 1362-1367 (1990).
6. Schmidt M, Maurer-Gebhard M, Groner B, Kohler G, Brochmann-Santos G, Wels W. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 18(9), 1711-1721 (1999).
7. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 74(11), 1749-1756 (1996).
8. Liu Z, Ballinger JR, Rauth AM, Bendayan R, Wu XY. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J. Pharm. Pharmacol. 55(8), 1063-1073 (2003).
9. Medina-Kauwe LK, Kasahara N, Kedes L. 3PO, a novel non-viral gene delivery system using engineered Ad5 penton proteins. Gene Ther. 8, 795-803 (2001). First description of the HerPBK10 carrier protein for tumor targeting.
10. Medina-Kauwe LK, Maguire M, Kasahara N, Kedes L. Non-viral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 8, 1753-1761 (2001).
11. Agadjanian H, Ma J, Rentsendorj A et al. Tumor detection and elimination by a targeted gallium corrole. Proc. Natl Acad. Sci. USA 106(15), 6105-6110 (2009). Shows that HerPBK10 is nonimmunogenic.
12. Sliwkowski MX, Schaefer G, Akita RW et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269(20), 14661-14665 (1994). One of the earliest reports indicating heregulin binds a heterodimer.
13. Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation. Biochemistry 29(50), 11024-11028 (1990).
14. Jeschke M, Wels W, Dengler W, Imber R, Stocklin E, Groner B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer 60(5), 730-739 (1995).
15. Van Der Horst EH, Weber I, Ullrich A. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. Int J. Cancer 113(5), 689-698 (2005).
16. Lewis GD, Lofgren JA, McMurtrey AE et al. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res. 56(6), 1457-1465 (1996).
17. Gregory Cw, Whang Ye, Mccall W et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin. Cancer Res. 11(5), 1704-1712 (2005).
18. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire Wl. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987). One of the earliest studies correlating HER2 amplification with breast cancer aggressiveness and recalcitrance to therapy.
19. Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors? Science 240(4860), 1795-1798 (1988).
20. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744 (1996).
21. Cobleigh MA, Vogel CL, Tripathy D et al. Efficacy and safety of herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
22. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726. (2002).
23. Kute T, Lack CM, Willingham M et al. Development of Herceptin resistance in breast cancer cells. Cytometry A 57(2), 86-93. (2004).
24. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8(5), 459-465 (2002). Among the earliest studies demonstrating a critical role of ErbB2 in heart maintenance.
25. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
26. Medina-Kauwe LK, Leung V, Wu L, Kedes L. Assessing the binding and endocytosis activity of cellular receptors using GFP-ligand fusions. BioTechniques 29, 602-609 (2000).
27. Medina-Kauwe LK. Non-viral mediated gene delivery for therapeutic applications. In:Gene Therapy for Neurological Disorders. Lowenstein P, Castro M (Eds). Taylor and Francis Group LLC, London UK, 115-140 (2006).
28. Medina-Kauwe LK, Xie J, Hamm-Alvarez S. Intracellular trafficking of nonviral vectors. Gene Ther. 12(24), 1734-1751 (2005).
29. Rentsendorj A, Agadjanian H, Ma J et al. New approach for targeting RNAi-mediated toxicity to cancer cells. Presented at: The American Society of Gene Therapy Annual Meeting. MA USA, 28 May- 1 June (2008).
30. Rentsendorj A, Xie J, Macveigh M et al. Typical and atypical trafficking pathways of Ad5 penton base recombinant protein: implications for gene transfer. Gene Ther. 13(10), 821-836 (2006).
31. Meyer M, Dohmen C, Philipp A et al. Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol. Pharm. 6(3), 752-762 (2009).
32. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 16(1), 163-169 (2008).
33. Christgen M, Lehmann U. MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol. Ther. 6(9), 1355-1357 (2007).
34. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 69(13), 5292-5293 (2009).
35. Hwang JY, Wachsmann-Hogiu S, Ramanujan VK et al. Multimodal wide-field two-photon excitation imaging: characterization of the technique for in vivo applications. Biomed. Opt. Express. 2(2), 356-364 (2011).
36. Hwang JY, Wachsmann-Hogiu S, Ramanujan VK et al. Multimode optical imaging system for preclinical applications in vivo: technology development, multiscale imaging, and chemotherapy assessment. Mol. Imaging Biol. doi: 10.1007/s11307-011-0517-z (2011) (Epub ahead of print).
37. Hwang Jy, Moffatt-Blue C, Equils O et al. Multimode optical imaging of small animals: development and applications. Proc. SPIE 6441, 644105 (2007).
38. Mohan P, Rapoport N. doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol. Pharm. 7(6), 1959-1973 (2010).
39. Karimi G, Ramezani M, Abdi A. Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. Phytother. Res. 19(10), 912-914 (2005).
40. Shuai Y, Guo JB, Peng SQ et al. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol. Lett. 170(1), 66-74 (2007).
41. Lis R, Capdet J, Mirshahi P et al. Oncologic trogocytosis with hospicells induces the expression of N-cadherin by breast cancer cells. Int. J. Oncol. 37(6), 1453-1461 (2010).
42. Shinohara ET, Maity A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Curr. Mol. Med. 9(9), 1034-1045 (2009).
43. Murakami M, Cabral H, Matsumoto Y et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci. Transl. Med. 3(64), 64ra62 (2011).
44. Oh K, Baik H, Lee A et al. The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system. Int. J. Mol. Sci. 10(9), 3776-3792 (2009).
45. Lechardeur D, Sohn KJ, Haardt M et al. Metabolic instability of plasmid DNA in the cytosol: A potential barrier to gene transfer. Gene Ther. 6(4), 482-497 (1999).
46. Pollard H, Toumaniantz G, Amos JL et al. Ca2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. J. Gene Med. 3(2), 153-164 (2001).
47. Zelphati O, Szoka FC. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl Acad. Sci. USA 93(21), 11493-11498 (1996). Presents the mechanism of oligonucleotide release from endosomes into the cytosol.
48. Samarsky DA, Fournier MJ, Singer RH, Bertrand E. The snoRNA box C/D motif directs nucleolar targeting and also couples snoRNA synthesis and localization. EMBO J. 17(13), 3747-3757 (1998).
49. Lange TS, Borovjagin AV, Gerbi SA. Nucleolar localization elements in U8 snoRNA differ from sequences required for rRNA processing. RNA 4(07), 789-800 (1998).
50. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110(4), 475-482 (2002).
51. Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65(12), 5317-5324 (2005).
52. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21(5), 797-802 (2010).
53. Medina-Kauwe Lk, Chen X. Using GFP-ligandfusions to measure receptor-mediated endocytosis in living cells. In: Vitamins and Hormones. Elsevier Science, CA, USA, 81-95 (2002).
54. Agadjanian H, Weaver JJ, Mahammed A et al. Specific delivery of corroles to cells via noncovalent conjugates with viral proteins. Pharm. Res. 23(2), 367-377 (2006).
55. Park JW, Hong K, Kirpotin DB et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8(4), 1172-1181 (2002).
56. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51(4), 691-743 (1999).
57. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2), 185-229 (2004).
58. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins avb3 and avb5 promote adenovirus internalization but not virus attachment. Cell 73(2), 309-319 (1993).
59. Fender P, Schoehn G, Foucaud-Gamen J et al. Adenovirus dodecahedron allows large multimeric protein transduction in human cells. J. Virol. 77(8), 4960-4964 (2003).